Jubilant Pharmova Ltd.

NSE: JUBLPHARMA | BSE: 530019 | ISIN: INE700A01033 | Industry: Pharmaceuticals
| Mid-range Performer
1079.4000 18.00 (1.70%)
NSE Sep 30, 2025 11:24 AM
Volume: 38,275
 

1079.40
1.70%
Prabhudas Lilladhar
Improvement in growth for LSI business remains opaque JUBILANT Q4FY20 earnings were higher than our estimate due to higher stockup in US generics, lower erosion in core portfolio and favourable forex. We assumed COVID impact to be realised in Q4FY20, but better availability of inventory and raw materials led to upbeat in EBITDA and EBITDA margin. We believe although Q4FY20 performance was better, COVID impact may drag...
Number of FII/FPI investors increased from 196 to 233 in Jun 2025 qtr.
More from Jubilant Pharmova Ltd.
Recommended